The brothers sold the company to Novartis in 2005 for $7.5 billion. Thomas Strungmann has since invested in a variety of other businesses, including a stake in the German soccer team FC Bayern Munich.
Thomas Strungmann is a German pharmaceutical entrepreneur with an estimated net worth of $8.1 billion. He and his twin brother Andreas made their fortune through the formation of Hexal AG, which became the second-largest generic drug maker in Germany. In 2005, the brothers sold the company to Novartis for $7.5 billion. Thomas has since invested in a variety of other businesses, including a stake in the German soccer team FC Bayern Munich.
Thomas Strungmann is a member of Richest Billionaires
Age, Biography and Wiki
💰 Net worth: $8.1 Billion (2024)
Thomas Strungmann Net Worth: Thomas Strungmann is a German pharmaceutical entrepreneur who has a net worth of $8.1 billion. Thomas Strungmann and his twin, Andreas, rose to riches together with the formation of generic drug maker Hexal AG, which transformed into the second-largest generic drug maker in the country.
An alumnus of Augsburg University in Business Administration, Thomas teamed up with his brother in 1986 to set up Hexal AG. They successfully run and developed the company until 2005, when they sold the business along with their 68% stake in Eon Lab (now based in the U.S.) to Novartis for $7.5 billion. Subsequently, the duo invested into several biotech companies based in Germany through their Athos Service GmbH and Santo Holding. Thomas Strungmann is also said to have an extensive collection of Swiss watches and modern art pieces in his possession. Away from business, he is a married man and a father of four.
